Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0486 master protocol in mature B-cell malignancies
CTR20252392Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of surovatamig in mature B-cell neoplasm (MBCN), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Started Aug 2025; status: active.
02
Drugs
surovatamig
03
Conditions
mature B-cell neoplasm (MBCN)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20252392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252392.